NCT06692075 Emergency Total ECLS vs Standard ACLS With ECMO Bailout for Survival in Refractory OHCA
| NCT ID | NCT06692075 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Taipei Medical University Shuang Ho Hospital |
| Condition | Out-of-hospital Cardiac Arrest (OHCA) |
| Study Type | INTERVENTIONAL |
| Enrollment | 332 participants |
| Start Date | 2024-11-01 |
| Primary Completion | 2028-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 332 participants in total. It began in 2024-11-01 with a primary completion date of 2028-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of the clinical trial is to learn if early extracorporeal life support ( ECLS ) will save more out-of-hospital cardiac arrest ( OHCA ) patients with good neurological outcome. It will also learn if emergency ECLS is safe in the OHCA rescue. Researchers aim to investigate if emergency total ECLS is better than standard advanced cardiac life support ( ACLS ) first, followed by bailout ECMO if required, for survival with favorable neurological outcome in OHCA patients. Participants meeting criteria of OHCA with witness, bystander CPR, shockable initial rhythm with repeated defibrillation, and transport time less than 30 min will be compared between total ECLS versus standard ACLS first with bailout ECMO protocols. All participants will receive emergency interventional coronary revascularization , intensive care unit therapy , cardiac ward care and up to 180 days of clinical follow up after survival .
Eligibility Criteria
Inclusion Criteria: 1. adults aged 18-75 years old 2. witnessed cardiac arrest with bystander CPR 3. initial shockable rhythm as ventricular fibrillation or pulseless ventricular tachycardia ( VF/pVT ) 4. repeated defibrillation shocks ( more than 2 ) by external defibrillator 5. estimated transportation time from 119 call to arrival at emergency service less than 30 minutes. Exclusion Criteria: 1. age less than 18 years or more than 75 years old 2. non-shockable initial rhythm, i.e. pulseless electrical activity or asystole 3. acute aortic dissection 4. acute massive pulmonary embolism 5. intracerebral hemorrhage 6. major trauma due to blunt, penetrating or burn injury 7. severe peripheral artery occlusion disease 8. known pregnancy 9. suicide, illicit drug overdose or intoxication 10. known pre-arrest modified Rankin score ( mRS ) more than 3 or cerebral performance category scale ( CPC ) more than 2 11. severe concomitant malignancy with expected life expectancy less than 1 year 12. signed and effective do-not-resuscitation ( DNR ) order 13. absolute contraindications to emergency coronary angiography, including known anaphylactic reaction to angiographic contrast media, acute gastrointestinal bleeding or internal bleeding.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06692075 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Out-of-hospital Cardiac Arrest (OHCA). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06692075 currently recruiting?
Yes, NCT06692075 is actively recruiting participants. Contact the research team at jiunnleelin@gmail.com for enrollment information.
Where is the NCT06692075 trial being conducted?
This trial is being conducted at New Taipei, Taiwan, New Taipei, Taiwan.
Who is sponsoring the NCT06692075 clinical trial?
NCT06692075 is sponsored by Taipei Medical University Shuang Ho Hospital. The trial plans to enroll 332 participants.